USPTO Deadlines
Next Deadline
1754 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20241015)
Due Date
October 15, 2030
Grace Period Ends
April 15, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 10, 2025 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS | Loading... |
| Feb 10, 2025 | CANT | T | CANCELLATION TERMINATED NO. 999999 | Loading... |
| Feb 10, 2025 | CAND | T | CANCELLATION DENIED NO. 999999 | Loading... |
| Dec 2, 2024 | PETC | T | CANCELLATION INSTITUTED NO. 999999 | Loading... |
| Oct 15, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Oct 15, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 30, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 30, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 10, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 21, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 5, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 5, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 5, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 9, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 9, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 9, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 9, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 25, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 26, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Platform as a service (PAAS) featuring computer software platforms for using genomics, bioinformatics and machine learning to provide insights into an individual's DNA variations that lead to poor drug response.
First Use Anywhere:
Jan 1, 2022
First Use in Commerce:
Jan 1, 2022
Classification
International Classes
042